Rezolute Inc is trading at $4.27 (-5.32%) as shares pull back from a sharp multi-day run-up fueled by encouraging interim Phase 3 upLIFT data for ersodetug in tumor hyperinsulinism.
- The decline appears to be driven by profit-taking and consolidation following the recent surge rather than any new negative company-specific catalysts.
- Broader market weakness is adding to the downward pressure, as growth stocks face headwinds from stronger-for-longer interest rate expectations.